Stay updated with breaking news from Markl Baum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly
/PRNewswire/ -- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative...
IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 Years
27.09.2022 - Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local ... Seite 1
NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial...